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a  b  s  t  r  a  c  t
Malignant eccrine spiradenoma (MES) is a rare malignancy of the eccrine sweat glands.
It  usually presents as a small, ﬁrm, reddish painful and small solitary nodule. Head and
neck  are rare locations. Etiology is unknown although previous trauma is believed to be an
implicated factor. MES arises over a prior benign spiradenoma. Clinical behavior is aggressive
with  a high rate of recurrences and distant metastases. Prognosis is poor. Diagnosis is based
on  histological ﬁndings and treatment must be aggressive from the beginning to achieve
the  best results.
Since Kersting and Helwig ﬁrst described the case in 1956, and Beekley et al., reported its
malignant transformation in 1971, only a few cases can be found in the literature.
Based on these particular features we report a case of a 75-year-old man  diagnosed on a
MES  that arises in a very unusual location, with a peculiar histopathology and behavior.
© 2011 SECOM. Published by Elsevier España, S.L. All rights reserved.
Espiradenoma  ecrino  maligno  en  el  surco  nasolabial.  Caso  clínico
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r  e  s  u  m  e  n
El espiradenoma ecrino maligno (EEM) es un tumor maligno poco frecuente de las glándulas
sudoríparas ecrinas. Suele presentarse como un pequen˜o nódulo eritematoso, ﬁrme, soli-
tario y doloroso. La cabeza y el cuello son una localización excepcional. Se desconoce la
Resección quirúrgica amplia etiología aunque se considera que un traumatismo previo es un factor implicado. El EEM
Seguimiento se  origina sobre un espiradenoma benigno previo. La conducta clínica es agresiva con una
elevada tasa de recidivas y metástasis a distancia. El pronóstico es infausto. El diagnóstico
se  basa en los hallazgos histológicos y el tratamiento ha de ser agresivo desde el principio
para  obtener los mejores resultados.
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Desde que, en 1956, Kersting y Helwig describieran el primer caso, y, en 1971, Beekley y cols.
documentaran su transformación maligna, sólo se han publicado unos pocos casos.
En  función de estas características especíﬁcas, describimos a un hombre de 75 an˜os de
edad,  en el que se estableció el diagnóstico de este tumor, originado en una localización
poco  habitual, con una histopatología y conducta peculiares.
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ccrine spiradenoma is an uncommon and slow growth tumor
f the eccrine sweat glands.1–3 It usually presents as a small,
rm, reddish painful and small solitary nodule. Head and neck
re rare locations.3,4 Etiology is unknown although previous
rauma is believed to be an implicated factor.5,6
Since Beekley et al.,7 in 1971, ﬁrst described malignant
ransformation of this tumor, less than 50 cases have been
eported in the literature.2–6,8–10 Clinical behavior is aggressive
ith a high rate of local recurrences and distant metas-
ases. Diagnosis is based on histopathological ﬁndings. Wide
ocal excision associated with cervical neck dissection is the
lective treatment.6,11 We  now report a peculiar case of a
alignant eccrine spiradenoma that arises, after surgical exci-
ion of a prior benign lesion, with an unusual behavior and
istological features.
ase  report 75-year-old man  was referred to our Oral and Maxillofacial
urgery Department with a lesion in the nasolabial fold (Fig. 1)
Fig. 1 – Primary lesion in the nasolabial fold.ublicado por Elsevier España, S.L. Todos los derechos reservados.
diagnosed histologically as a malignant eccrine spiradenoma,
after three surgical excisions in another Surgery Department.
According to the diagnosis, a MRI and a radionuclide bone
scan were performed. A 2.7 × 2.3 × 2.1 cm nodular and bad
deﬁned lesion was located in the left zygomatic area inﬁl-
trating skin and subcutaneous tissue (Fig. 2) as well as four
metastatic lesions in the occipital, right temporal, sphenoid
and superior edge of the left scapula.
The tumor was diagnosed as a malignant eccrine spirade-
noma stage IV so that palliative treatment with chemotherapy
was performed. Partial bone response was obtained since radi-
ological point of view but primary tumor kept on growing.
Although tumoral stage was advanced, we  decided, accord-
ing to the patient, performing a radical surgery treatment.
Then, a FNAC of the primary lesion conﬁrmed the diagnosis
and a wide surgical excision of the tumor with neck dissection
and reconstruction with a cervicopectoral ﬂap was planned.
Histopathological examination revealed an encapsulated
tumor composed by two cell types disposed in solid groups and
areas with glandular, squamous and even sarcomatoid differ-
entiation. Mitosis rate was so high and wide necrotic areas
were frequently seen. The capsule had tumoral invasion foci
(Fig. 3).
No one of the twelve cervical lymph nodes isolated was
inﬁltrated by the tumor.
Eight months later, the patient presented a recurrence on
the cervicopectoral scar, near the lips. According to this, a
new resection was performed again obtaining histological free
margins (Fig. 4).
Fig. 2 – Facial MRI  showing the lesion (white arrow).
182  r e v e s p c i r o r a l m a x i l o f a c . 2 0 1 2;3  4(4):180–184Fig. 3 – Histological ﬁndings (HE 400×).
Nowadays, three years after last surgery there have been
no signs of local recurrences and metastatic lesions have been
controlled by chemotherapy (Fig. 5).
DiscussionThis report tries to make a special emphasis concerning
a proper management of eccrine spiradenoma, frequently
benign, but, as in our case and due to an incorrect initial
Fig. 4 – Surgical bed with adequate safety margins.
Fig. 5 – Postoperative aspect of the patient from lateral and
frontal view. Notice the good aesthetic result.management, sometimes malignant. Since Kersting and Hel-
wig ﬁrst described the case in 1956,9 and Beekley et al.,7
reported its malignant transformation in 1971, only a few
cases can be found in the literature.2–6,8–10
Eccrine spiradenoma is usually benign and may occur in
infancy but most commonly arises in young people (2nd to
4th decades) as a small, ﬁrm and reddish painful solitary nod-
ule (0.5–3 cm), although bigger tumors have been described
(10 cm).1,3,8,9 Ulceration is extremely infrequent.1,5
 o f a c
i
e
i
g
l
d
a
p
o
i
c
s
r
t
a
h
h
p
m
p
n
r
T
v
s
m
p
w
h
r
m
c
a
l
s
n
t
t
b
t
r
p
t
c
i
a
r
h
p
r
case report with pulmonary metastasis. Pathol Int.r e v e s p c i r o r a l m a x i l
Malignant form of eccrine spiradenoma (MES) is extremely
nfrequent and only 50 cases have been reported in the lit-
rature. It may develop de novo or most frequently, arises
n pre-existing benign eccrine spiradenoma as a sudden
rowth or pain in people over 50 years old after a variable
atent period (may  be as long as 75 years), with no gender
ifferences.2,4,6,8,9,12,13 It tends to preferentially involve trunk
nd extremities (92% of reported cases) and head and neck
resentation is extremely rare, as in our case.12
Multiple cases have been described associated with
ther neoplasms as cylindromas, hidradenomas or trichoep-
theliomas into the Brooke–Spiegler syndrome. In these
ases, lesions combine features of both cylindromas and
piradenomas.1,4,5,8
Since MES  has an aggressive clinical behavior and a high
ate of local recurrences (32–58%) and distant metastases to
he lymph nodes (35–44%), bone and lung,2,4,8,14 a proper man-
gement should begins with a proper diagnosis based on
istopathological ﬁndings.
Such ﬁndings include proliferation of atypical cells with
yperchromatic nuclei, increased mitoses, nuclear pleomor-
hism and loss of periodic acid-Schiff-positive basement
embrane and loss of the typical dual cell population dis-
osed in cords.3–6,8,10,12,13
Another microscopic features may be present as areas of
ecrosis, focal squamous differentiation, invasion of the sur-
ounding tissues and increased vascularization of the tumor.
he last condition can lead to diagnostic confusion with a
ascular neoplasm.12
Immunohistochemically, MES  exhibit variable expres-
ion of cytokeratins, carcinoembryonic antigen, epithelial
embrane antigen and S100 protein. Overexpression of
53 protein in benign spiradenomas has been associated
ith malignant transformation, usually into a carcinoma;
owever, carcinosarcomatous transformation has also been
eported.12
Areas of spiradenoma near or in transition with a
alignant tumor such as rhabdomyosarcoma, osteosar-
oma, leiomyosarcoma, and chondrosarcoma may be present
lthough less frequently.4,8
All these variable and inconstant histological features can
ead to a mistaken diagnosis with other skin malignances6,13
uch as carcinoma, basal cell carcinoma, clear cell hidrade-
oma or malignant condroid syringoma.8 So, we emphasize
o make a correct and close histological examination in order
o avoid incorrect treatments.
The mainstay of therapy is surgical excision, which may
e curative in some cases.12 According to our experience and
he medical literature, every tumor diagnosed as eccrine spi-
adenoma should be widely resected even benign, in order to
revent malignization and local recurrences.1,2,5,8,9
Cervical lymph nodes should be dissected if tumor metas-
ases are suspected clinically to complete the treatment if
ervical disease is present and to prevent lympathic spread
f the neck is staged as N0.2,4,6,11,12
The usefulness of other therapeutic alternatives such
s hormonal therapy with tamoxifen, chemotherapy and
2,4–6,8,9,11adiotherapy remains to be determined and they
ave been used unsuccessfully in the treatment of these
atients.6 . 2 0 1 2;3  4(4):180–184 183
We  do not agree with these thoughts, based on our clinical
case. As described above, the patient was diagnosed on MES
stage IV with bone metastases. He received six cycles of CDDP-
5-FU-folinic acid obtaining an almost complete bone response.
This ﬁnding should represent a new chemotherapy schedule
useful in selected cases.
MES usually metastasizes to regional lymph nodes and
less frequently to lung, brain and liver. While distant metas-
tases are uncommon, they generally portend an ominous
prognosis.12 In spite of this condition, it is noticeable that our
patient is still alive despite he was initially presented with
bone distant metastases.
The overall prognosis is so poor that Meyer et al.8 reported
survivals of 36 months after diagnosis with a mortality rate of
22%. Other authors as Herzberg et al.11 ﬁnd a mortality rate of
20%.
It is noticeable that our patient, three years after the
last surgery, keeps still alive with a good quality of life.
Nevertheless, postoperative long-term follow-up is neces-
sary in all the patients to prevent any local or metastatic
recurrence.6
Conclusions
We  are face to face with a rare tumor of the eccrine sweat
glands. Malignant forms are extremely uncommon although
described. Diagnosis is complicated and is based on histolog-
ical ﬁndings. Recurrences after treatment are frequent and
often occur after incomplete tumor excisions so that aggres-
sive surgical treatment must be performed although the tumor
is benign.
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